Approval of a cheap version of HIV-prevention shot lenacapavir raises hopes in low-income countries
Headline from Anchorage Daily News
The announcement is a big step toward making the extremely effective drug available inexpensively and quickly in 120 low- and middle-income countries.
Anchorage Daily News's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.
FDA approved the first generic of twice-yearly HIV-prevention shot lenacapavir at about $40 a year for 120 resource-limited countries; U.S. brand lists at $28,218.
The U.S. Food and Drug Administration on Monday approved a low-cost version of a twice-yearly HIV prevention shot, bringing the breakthrough drug closer to market in low-income countries.
The drug is expected to cost $40 a year per person in the countries where it will be available, the same price as daily preventive pills available now.
Identical headlines usually mean shared wire copy. They are counted as separate articles but are not independent confirmation.
